As per the findings of a crossover study, a single dose of loratadine-pseudoephedrine tablet (LP) rapidly improved nasal airflow in patients with allergic rhinitis and nasal congestion. Comparatively, fluticasone propionate nasal spray (FP) did not demonstrate this same benefit. This phase 4, placebo-controlled, single-center, double-blinded study was carried to explore numerically, nasal airflow alterations offered by a single dose of LP and FP in participants experiencing allergic rhinitis symptoms, including nasal congestion.

People having a documented sensitivity to ragweed pollen were randomly assigned to receive one of four therapy sequences, and their peak nasal inspiratory flow (PNIF) was estimated in a span of four hours following ragweed pollen exposure in an environmental exposure unit. The average alteration in PNIF was more with LP in the course of the study, when compared with FP and placebo, as shown in Table 1:

Nevertheless, FP did not elicit a substantial alteration compared with the placebo spray. After one hour of post-dose, LP demonstrated a clinically significant 31% rise in PNIF, whereas FP yielded only an 8.6% rise. Measurable nasal airflow improvements are linked with the opening of nasal passages, permitting congested people to freely breathe. Compared to FP, LP effectively alleviates the symptoms of allergic rhinitis, concluded the study authors.